Table 1

Synthesis of 1,25(OH)2D3 by human prostatic cells and cancer cell linesa

Normal cells1,25(OH)2D3 productionbBPH1,25(OH)2D3 productionbPrimary cancerGleason grade1,25(OH)2D3 productionbCancer cell lines1,25(OH)2D3 productionb
E-CZ-12.04BPH-11.37E-CA-13/30.17LNCaP0.006
E-CZ-22.25BPH-21.46E-CA-23/40.40PC-30.071
E-CZ-31.27BPH-31.71E-CA-33/40.24DU 1450.279
E-CZ-42.10BPH-41.65E-CA-43/30.41MDA-PCa 2b0.34
E-PZ-12.14BPH-51.21E-CA-53/30.21
E-PZ-22.60BPH-61.57E-CA-63/40.23
E-PZ-32.10BPH-71.61E-CA-73/30.27
E-PZ-41.23BPH-81.28E-CA-83/30.31
E-PZ-51.19E-CA-93/30.46
E-PZ-62.34E-CA-103/30.72
E-PZ-73.10E-CA-1130% IDCc/70% 40.31
E-PZ-82.63E-CA-123/30.27
E-PZ-92.43E-CA-134/30.17
E-PZ-102.31E-CA-14IDC1.17
E-PZ-112.70E-CA-15Antiandrogen therapy1.26
E-PZ-123.01
E-PZ-131.30
E-PZ-142.92
  • a Values represent means of assays performed in triplicate. Strains E-CZ-2, E-PZ-8, E-CA-9, E-CA-14, E-CA15, and all four cancer cell lines were evaluated two and/or three times with values differing by <10%.

  • b pmol/mg protein/h.

  • c IDC, intraductal carcinoma.